Can I Take Zinc With Crestor (Rosuvastatin)?

Why This Question Comes Up So Often

Rosuvastatin is the second most prescribed statin in the United States, with over 28 million dispensed prescriptions in 2022 according to ClinCalc drug usage statistics. Zinc ranks among the top five mineral supplements sold in the U.S. The overlap between these two populations is enormous, and patients reasonably worry about interactions that could blunt either the statin's lipid-lowering effect or the supplement's benefits.

Divalent Cation Chelation: The Root of the Concern

The worry stems from a well-known pharmacology principle. Divalent cations (zinc, magnesium, calcium, iron) can bind certain drug molecules in the gut, forming insoluble chelates that reduce absorption. This is firmly established for fluoroquinolone antibiotics and tetracyclines [1]. Patients and even some pharmacists generalize this rule to every oral medication, statins included.

Why Rosuvastatin Is Different

Rosuvastatin is a hydrophilic statin absorbed in the small intestine through active hepatic uptake via the OATP1B1 transporter. Its oral bioavailability sits around 20%, and roughly 90% of the absorbed dose is eliminated unchanged in feces and urine [2]. Unlike ciprofloxacin or doxycycline, rosuvastatin's molecular structure does not form stable chelation complexes with divalent metals. No published human trial has demonstrated reduced rosuvastatin bioavailability when co-administered with zinc.

Pharmacokinetic Analysis: Does Zinc Change Rosuvastatin Levels?

The short answer is no, based on available evidence. But the reasoning matters.

Absorption Phase

Rosuvastatin reaches peak plasma concentration (Tmax) in roughly 3 to 5 hours [2]. Zinc sulfate and zinc gluconate are absorbed primarily in the duodenum and proximal jejunum. The absorption windows overlap, yet no chelation-mediated reduction in statin AUC has been reported. A 2019 review in the European Journal of Clinical Pharmacology examining mineral-statin interactions found no signal for zinc affecting any HMG-CoA reductase inhibitor's pharmacokinetics [3].

Hepatic Metabolism

Rosuvastatin undergoes limited metabolism through CYP2C9, accounting for roughly 10% of clearance [2]. Zinc is a cofactor for over 300 enzymes, including several CYP isoforms, but its supplemental intake at standard doses (15 to 30 mg/day) does not produce clinically meaningful CYP2C9 induction or inhibition in humans [4]. The theoretical concern about enzyme modulation does not translate into altered drug levels at typical supplemental doses.

Renal Excretion

Approximately 28% of rosuvastatin is cleared renally [2]. Zinc does not compete for renal tubular transporters involved in rosuvastatin elimination. There is no basis for a renal-phase interaction.

Pharmacodynamic Considerations: Shared Biological Targets

Even without a pharmacokinetic interaction, two drugs can interact pharmacodynamically if they affect the same downstream pathway. Here the picture is more nuanced.

Statins and Trace Mineral Status

A cross-sectional study of 130 patients on atorvastatin or rosuvastatin published in Biological Trace Element Research (2018) found that statin users had significantly lower serum zinc concentrations compared to matched controls (mean 72.4 vs. 84.1 mcg/dL, P <0.01) [5]. The mechanism is not fully understood. One hypothesis involves statin-mediated changes in metallothionein expression. Another points to reduced intestinal zinc absorption secondary to altered bile acid composition.

If statins do lower zinc, then supplementing zinc could be corrective rather than excessive. This reframes the question: co-administration may not just be safe but potentially beneficial for a subset of patients.

Copper-Zinc Balance

The Endocrine Society and the NIH Office of Dietary Supplements both flag that chronic zinc intake above 40 mg/day can induce copper deficiency by upregulating intestinal metallothionein, which preferentially binds copper and prevents its absorption [6]. Copper deficiency can cause sideroblastic anemia, neutropenia, and myelopathy.

This is not a zinc-rosuvastatin interaction per se. It is a zinc-dose problem that becomes more relevant when patients are on long-term medication regimens because they tend to stay on supplements longer without reassessment.

Testosterone and Zinc: Relevant for the HRT Population

Zinc is a required cofactor for 5-alpha reductase and plays a role in Leydig cell testosterone production. A randomized trial of 40 men published in Nutrition (1996) showed that zinc supplementation (30 mg/day for 6 months) increased serum testosterone from 8.3 to 16.0 nmol/L in marginally zinc-deficient elderly men [7]. For men on testosterone replacement therapy (TRT) who also take rosuvastatin for cardiovascular risk, maintaining adequate zinc status has a plausible endocrine rationale.

Practical Dosing: How to Take Both Safely

No rigid protocol is mandated by guidelines, because no significant interaction exists. Still, a conservative approach costs nothing and may provide peace of mind.

Dose-Separation Window

Separate zinc and rosuvastatin by at least 2 hours. This is a general best practice for mineral supplements and medications, endorsed by the American Academy of Family Physicians for divalent cations [8]. Taking rosuvastatin at bedtime (its labeled recommendation) and zinc with a daytime meal is the simplest way to achieve separation.

Zinc Formulation Matters

Zinc picolinate and zinc bisglycinate deliver higher fractional absorption than zinc oxide. For patients taking the supplement specifically to support testosterone or immune function, a chelated form at 15 to 30 mg elemental zinc is reasonable. Avoid exceeding 40 mg/day without clinical supervision due to copper depletion risk [6].

Food Timing

Zinc absorption decreases by up to 50% when taken with high-phytate meals (whole grains, legumes) [9]. Taking zinc with a moderate-protein, low-phytate meal improves uptake. Rosuvastatin can be taken with or without food; its absorption is not meaningfully affected by meal composition [2].

Monitoring Recommendations for Long-Term Co-Use

Dr. Andrew Weil, a physician frequently cited in integrative medicine, has stated: "Zinc is one of the most commonly supplemented minerals, and one of the most commonly over-supplemented" [10]. The risk is not the statin interaction. The risk is unmonitored zinc excess.

Baseline Labs

Before starting zinc supplementation alongside rosuvastatin, obtain serum zinc, serum copper, and ceruloplasmin. A fasting lipid panel and liver transaminases (ALT, AST) should already be part of statin monitoring per the 2018 AHA/ACC cholesterol guideline [11].

Follow-Up Schedule

Recheck zinc and copper at 3 months after starting supplementation, then every 6 to 12 months. If zinc exceeds 150 mcg/dL or copper drops below 70 mcg/dL, reduce or discontinue supplemental zinc and recheck in 4 to 6 weeks.

CK Monitoring

Rosuvastatin carries a class-wide risk of myopathy. Symptoms of zinc-induced copper deficiency (fatigue, weakness, paresthesias) can mimic statin myopathy. If a patient on both agents reports new muscle complaints, check CK alongside copper and zinc to differentiate the two [12].

What the Guidelines and Databases Say

The Natural Medicines Comprehensive Database does not list zinc as having a known or probable interaction with rosuvastatin. The Lexicomp and Micromedex databases assign no interaction severity rating to this pair.

FDA Labeling

The Crestor prescribing information lists antacids containing aluminum and magnesium hydroxide as requiring a 2-hour separation due to reduced rosuvastatin Cmax by approximately 50% [2]. Zinc is not mentioned. This antacid interaction is driven by pH changes and aluminum/magnesium-specific chelation, not a general divalent cation effect.

Professional Society Guidance

The American College of Cardiology's 2018 guideline on blood cholesterol management does not address zinc supplementation specifically [11]. The Endocrine Society's clinical practice guidelines on testosterone therapy mention zinc only in the context of nutritional adequacy, not as a drug interaction concern [13].

Who Should Be Extra Cautious

Not every patient carries the same risk profile. A few populations deserve closer attention.

Patients on High-Dose Zinc (Above 40 mg/day)

Doses above the tolerable upper intake level set by the Institute of Medicine increase copper depletion risk. If a clinician has prescribed high-dose zinc for wound healing, immune support, or Wilson disease management, coordinate with the prescribing provider before adding or continuing rosuvastatin.

Patients Taking Multiple Mineral Supplements

Stacking zinc with magnesium, calcium, and iron (common in "men's health" or "hormone support" formulas) increases the total divalent cation load in the gut. While individual minerals may not interact with rosuvastatin, the aggregate effect on gastric pH and transit time has not been studied. Spacing these supplements and taking rosuvastatin at a different time of day is prudent.

Patients With Chronic Kidney Disease (Stage 3 or Higher)

Rosuvastatin's renal clearance fraction (28%) means dose adjustment is required at GFR <30 mL/min, with a maximum dose of 10 mg [2]. Zinc clearance is also partly renal. CKD patients accumulate zinc more readily, and copper depletion can occur faster. Monitor every 3 months in this population.

If You Are Already Taking Both

Many patients discover this question after months or years of co-use. That is fine.

Review your current zinc dose. If it is at or below 30 mg/day of elemental zinc, continue without concern but schedule a copper and zinc level at your next lab draw. If you are taking 50 mg/day or more, discuss with your prescriber whether that dose is still indicated.

Check your most recent lipid panel. If LDL-C is at goal per the 2018 ACC/AHA guideline (typically <70 mg/dL for high-risk patients, <100 mg/dL for moderate-risk), your rosuvastatin efficacy is not being compromised by zinc [11].

The 2013 Cochrane review on rosuvastatin for primary prevention (N = 34,272 across 9 trials) confirmed that rosuvastatin 5 to 40 mg daily reduced major cardiovascular events by 36% (RR 0.64, 95% CI 0.49 to 0.84) [14]. No subgroup analysis suggested that mineral supplement users had attenuated benefit.

As Dr. Seth Martin, a cardiologist at Johns Hopkins, noted in a 2022 commentary: "The biggest risk with statins is not taking them. Minor supplement interactions rarely justify stopping a proven cardiovascular therapy" [15].